Tweeter button Delicious button Digg button Stumbleupon button
Category Archives: fatty liver disease
Fatty Liver Disease | BergaMet's Significant Effect In Fatty Liver Disease Prompts Call For US Research Proposals

DENVER, July 1, 2014 /PRNewswire/ — A recent New York Times article (“Threat Grows from Liver Illness Tied to Obesity”, June 13 2014) alerting millions to the growing prevalence and seriousness of fatty liver disease revealed a stark and very concerning reality about therapeutic options. There are currently no drugs approved for either NAFLD (nonalcoholic fatty liver disease) or NASH    .. more …

Facebook Twitter Email

Fatty Liver Disease | New Data Presented At Digestive Disease Conference May Change Prognosis For Many Patients

CHICAGO, May 6, 2014 /PRNewswire/ –Research presented this week at Digestive Disease Week (DDW) provides insight into the development and new treatments of diseases, such as nonalcoholic fatty liver disease, colorectal cancer and ulcers. Key studies presented include: Weight-loss surgery can reduce liver damage . Bariatric surgery, which is best known for its ability to help patients lose weight,    .. more …

Facebook Twitter Email

Fatty Liver Disease | Low Vitamin D Linked To Fatty Liver Disease In UK Children

The research, conducted by the King’s College Hospital Paediatric Liver Centre and the University of Surrey’s School of Biosciences and Medicine, and funded by the Children’s Liver Disease Foundation retrospectively analysed the medical records of 120 paediatric patients with NAFLD.The findings could carry significant implications for UK clinicians in light of the nation’s rising number of    .. more …

Facebook Twitter Email

Fatty Liver Disease | First Cohort Results In Galectin Therapeutics' Phase 1 Trial Reveal Biomarker Evidence Of Therapeutic Effect On …

The Phase 1 multi-center, blinded (to healthcare providers and patients) clinical trial is being conducted in patients with NASH with advanced fibrosis (Brunt Stage 3) who receive four doses of GR-MD-02 over a 42-day period. Each of the three planned cohorts consists of eight patients, six randomized to receive active drug and two randomized to receive placebo. Eight U.S. clinical sites with    .. more …

Facebook Twitter Email

Fatty Liver Disease | Preclinical Study Demonstrates Effect Of Galectin Inhibitor On Serum Biomarker In Fatty Liver Disease With Fibrosis

As previously reported and published in PLOS ONE, the same study showed that GR-MD-02 improved all components of NASH in mice, including fibrosis [ ].GR-MD-02 is a proprietary molecule that binds to and inhibits galectin proteins, predominantly galectin-3. Patient enrollment is complete in cohort 1 of a blinded Phase 1 clinical trial of GR-MD-02 for patients with NASH with advanced fibrosis. No    .. more …

Facebook Twitter Email

Fatty Liver Disease | Research And Markets: Fatty Liver Disease Global Clinical Trials Review, H2 2013: Profiles Players Such As Biovil …

DUBLIN–(BUSINESS WIRE)– Research and Markets ( ) has announced the addition of the “Fatty Liver Disease Global Clinical Trials Review, H2, 2013″ report to their offering. The clinical trial report, Fatty Liver Disease Global Clinical Trials Review, H2, 2013” provides data on the Fatty Liver Disease clinical trial scenario. This report provides elemental information and data relating to the    .. more …

Facebook Twitter Email

Fatty Liver Disease | Published Preclinical Study Demonstrates Therapeutic Effect Of Galectin Inhibitors In Fatty Liver Disease With Fibrosis

In the study, NASH-induced mice were treated with GM-CT-01 and GR-MD-02 at two different points — early fibrosis and later more severe fibrosis. The studies evaluated twice-weekly, dose escalation of once weekly by intravenous administration, as well as evaluated different routes of administration including intravenous, subcutaneous and oral.Results revealed that treatment with GR-MD-02    .. more …

Facebook Twitter Email

Fatty Liver Disease | More Small Cap Regulatory Reform Necessary

The Jumpstart Our Business Startups Act (JOBS Act), passed in April of 2012, stands as a rare Congressional acknowledgment that legislators and regulators had gone too far in stifling small business growth and access to capital markets. In particular, the JOBS Act is supposed to ease restrictions on private securities issuers and to relax the decade-old Sarbanes-Oxley (Sarbox) rules that are    .. more …

Facebook Twitter Email

Fatty Liver Disease | Sugar Intake Not Directly Related To Liver Disease
fatty liver disease

Researchers conducted a double-blind study of healthy, but centrally overweight men to compare the effects of high intakes of two types of sugar, glucose and fructose, in two conditions — weight-maintaining (moderate-calorie diet) and weight-gaining (high-calorie diet). In the weight-maintaining period, men on neither diet developed any significant changes to the liver. However, in the    .. more …

Facebook Twitter Email

Fatty Liver Disease | Sugar Intake Not Directly Linked With Fatty Liver Disease
fatty liver disease

Washington, Nov 4 (ANI): A new study has claimed that sugar intake is not directly associated with nonalcoholic fatty liver disease , as it was earlier believed. Rather, high-calorie diets promote the progression of this serious form of liver disease .Researchers conducted a double-blind study of healthy, but centrally overweight men to compare the effects of high intakes of two types of sugar,    .. more …

Facebook Twitter Email

Next Page

Important Disclaimer: Article Comments provided are for general information purposes only and are not intended to substitute for informed professional medical, psychological, tax, accounting, legal, investment, or any other professional advice. We expressly disclaim liability for any product, manufacturer, distributor, service or service provider mentioned or any opinion expressed in these comments or anywhere else within the site. Lastly, we do not endorse any article or comment. Use at your own risk.